Brief: Eiger Biopharmaceuticals Reports Q4 And Full Year 2022 Financial Results And Provides Business Update
16/03/2023 21:35
March 16 (Reuters) - Eiger BioPharmaceuticals Inc
EIGR.O :
* EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR
2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* EIGER BIOPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.57
Source text for Eikon: ID:nPn3xYGHya
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview